Astellas Pharma Inc. - Cost of Goods Sold Including Depreciation and Amortization

Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Cost-of-Goods-Sold-Including-Depreciation-and-Amortization" stands at 441.02 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Astellas Pharma Inc.'s second quarter result of 138.25 Billion JPY for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 45.79 percent compared to it's first quarter result.

Also, Astellas Pharma Inc.'s second quarter result of 138.25 Billion JPY for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 18.24 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s second quarter result of 441.02 Billion JPY for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 5.08 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 13.13 percent compared to the value the year prior.
The 1 year change in percent is 13.13.
The 3 year change in percent is 57.55.
The 5 year change in percent is 71.33.
The 10 year change in percent is 28.77.

The Serie's long term average value is 312.15 Billion Japanese Yens. It's latest available value, on 09/30/2025, is 41.29 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2020, to it's latest available value, on 09/30/2025, is +81.62%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.